财务摘要(报告期)(KalVista Pharmaceuticals Inc)
2024年一季报 | 2023年年报 | 2023年三季报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年三季报 | 2022年中报 | 2022年一季报 | |
---|---|---|---|---|---|---|---|---|---|
每股指标: | |||||||||
每股收益EPS基本(元) | -0.87 | -3.44 | -2.37 | -1.54 | -0.74 | -3.33 | -2.58 | -1.84 | -0.94 |
每股净资产(元) | 4.01 | 4.86 | 2.56 | 3.32 | 4.07 | 4.71 | 5.40 | 5.85 | 6.70 |
每股经营现金净流量(元) | -0.95 | -2.58 | -2.15 | -1.36 | -0.78 | -2.21 | -2.14 | -1.77 | -0.93 |
每股现金流量净额(元) | - | -0.57 | -0.96 | 0.04 | -0.20 | 0.75 | 1.59 | 0.32 | 0.29 |
盈利能力: | |||||||||
净资产收益率平均(%) | -21.32 | -68.90 | -65.70 | -38.46 | -16.86 | -53.69 | -36.05 | -27.55 | -13.18 |
总资产净利率(%) | -18.57 | -60.51 | -55.18 | -32.90 | -14.74 | -48.00 | -32.70 | -24.71 | -11.93 |
投入资本回报率ROIC(%) | -21.75 | -76.62 | -75.27 | -50.92 | -21.28 | -61.91 | -45.69 | -30.46 | -14.51 |
收益质量: | |||||||||
营业利润/利润总额(%) | 109.33 | 110.90 | 112.19 | 111.09 | 114.91 | 119.34 | 118.83 | 115.23 | 114.21 |
资本结构: | |||||||||
资产负债率(%) | 13.69 | 12.24 | 22.27 | 17.51 | 13.10 | 12.11 | 9.35 | 11.68 | 9.73 |
权益乘数 | 1.16 | 1.14 | 1.29 | 1.21 | 1.15 | 1.14 | 1.10 | 1.13 | 1.11 |
产权比率 | 0.16 | 0.14 | 0.29 | 0.21 | 0.15 | 0.14 | 0.10 | 0.13 | 0.11 |
流动资产/总资产(%) | 95.72 | 95.87 | 91.34 | 92.69 | 93.46 | 94.06 | 94.43 | 92.86 | 93.47 |
非流动资产/总资产(%) | 4.28 | 4.13 | 8.66 | 7.31 | 6.54 | 5.94 | 5.57 | 7.14 | 6.53 |
流动负债/负债合计(%) | 81.79 | 79.13 | 75.35 | 73.06 | 67.30 | 67.78 | 61.00 | 59.50 | 54.84 |
非流动负债/负债合计(%) | 18.21 | 20.87 | 24.65 | 26.94 | 32.70 | 32.22 | 39.00 | 40.50 | 45.16 |
归属母公司股东的权益/投入资本(%) | 102.64 | 101.46 | 97.44 | 141.16 | 125.61 | 126.83 | 155.75 | 115.74 | 113.93 |
偿债能力: | |||||||||
流动比率 | 8.55 | 9.90 | 5.44 | 7.25 | 10.60 | 11.46 | 16.55 | 13.36 | 17.51 |
速动比率 | 8.55 | 9.90 | 5.44 | 7.25 | 10.60 | 11.46 | 16.55 | 13.36 | 17.51 |
货币资金/流动负债(%) | 142.11 | 139.38 | 120.54 | 324.86 | 349.62 | 374.12 | 732.80 | 340.86 | 389.02 |
营业利润/流动负债(%) | -197.29 | -615.80 | -480.92 | -331.47 | -205.87 | -737.57 | -681.91 | -461.11 | -270.38 |
经营活动产生的现金流量净额/流动负债(%) | -179.47 | -391.24 | -387.53 | -262.27 | -189.15 | -500.67 | -453.43 | -382.83 | -233.66 |
归属母公司股东的权益/负债合计(%) | 630.68 | 716.75 | 348.96 | 471.03 | 663.59 | 726.09 | 969.36 | 755.92 | 927.32 |
经营活动产生的现金流量净额/负债合计(%) | -146.79 | -309.59 | -292.01 | -191.61 | -127.30 | -339.37 | -276.58 | -227.78 | -128.15 |
营业利润/负债合计(%) | -161.37 | -487.28 | -362.38 | -242.17 | -138.56 | -499.94 | -415.95 | -274.37 | -148.28 |
成长能力: | |||||||||
总资产同比增长率(%) | 24.86 | 28.49 | -43.99 | -14.80 | -12.06 | -10.14 | -9.59 | -33.21 | -29.64 |
每股净资产同比增长率(%) | -1.36 | 3.10 | -52.62 | -43.12 | -39.29 | -37.50 | -36.23 | -37.19 | -33.04 |
总负债同比增长率(%) | 30.49 | 29.96 | 33.42 | 27.71 | 18.31 | 18.04 | 11.16 | 16.45 | 20.70 |
基本每股收益同比增长率(%) | -17.57 | -3.30 | 8.14 | 16.30 | 21.28 | 0.89 | -8.40 | -26.03 | -42.42 |
归属母公司股东的权益同比增长率(%) | 24.02 | 28.29 | -51.97 | -20.42 | -15.33 | -13.00 | -11.30 | -36.78 | -32.67 |
营业利润同比增长率(%) | -51.98 | -26.67 | -16.23 | -12.72 | -10.55 | -14.76 | -13.38 | -21.06 | -34.84 |
股东权益合计同比增长率(%) | 24.02 | 28.29 | -51.97 | -20.42 | -15.33 | -13.00 | -11.30 | -36.78 | -32.67 |
营运能力: | |||||||||
衍生指标: | |||||||||
现金及现金等价物净增加额TTM(元) | -61,993,000.00 | 19,081,000.00 | 11,546,000.00 | 25,506,000.00 | 39,472,000.00 | -7,906,000.00 | -10,480,000.00 | -19,860,000.00 | 27,850,000.00 |
利润总额TTM(元) | -108,300,000.00 | -100,575,000.00 | -95,182,000.00 | -92,907,000.00 | -90,715,000.00 | -91,880,000.00 | -89,272,000.00 | -82,339,000.00 | -73,182,000.00 |
投入资本(元) | 168,350,000.00 | 203,615,000.00 | 90,912,000.00 | 81,077,000.00 | 110,923,000.00 | 126,964,000.00 | 118,419,000.00 | 124,253,000.00 | 144,456,000.00 |
经营活动产生的现金流量净额TTM(元) | -96,762,000.00 | -78,480,000.00 | -79,249,000.00 | -75,261,000.00 | -79,414,000.00 | -84,190,000.00 | -83,141,000.00 | -78,134,000.00 | -62,390,000.00 |
归属母公司净利润TTM(元) | -108,300,000.00 | -100,575,000.00 | -95,182,000.00 | -92,907,000.00 | -90,715,000.00 | -91,880,000.00 | -89,272,000.00 | -82,339,000.00 | -73,182,000.00 |